Featured Entrepreneurs

Since 2010, MassChallenge has accelerated 1,975 startups that have raised more than $4.3 billion in funding, generated more than $2.5 billion in revenue, and created more than 121,000 total jobs. 

Our startups

Be inspired. Search our startups.

Velox Therapeutics

Thrombosis is a leading cause of death in developed countries. The currently used antithrombotics are associated with an increased risk of severe bleeding, which can be life threatening. The inhibition of a novel target, FXI, was found to efficiently prevent thrombosis without causing bleeding side effects, providing a much safer strategy. We have developed the first peptide-based FXI inhibitor, which shows a superior anti-coagulation effect, lasting for more than 10 hours in mice.
We have developed a novel anticoagulant that does not increase the bleeding risk, thus overcoming the safety issues related to current drugs

Connect with Velox Therapeutics

Velox Therapeutics


2018 Platinum Switzerland

Sub industry

Therapeutics (Pharma / Biotech)


MassChallenge strengthens the global innovation ecosystem by accelerating high-potential startups across all industries, from anywhere in the world.